5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)-

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

34 API Suppliers, 14 USDMF, 14 CEP/COS, 6 JDMF, 3 EU WC, 10 KDMF, 7 NDC API, 19 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

62 Drugs in Development

62 Drugs in Development

INTERMEDIATES

2 Intermediates Suppliers

2 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

212 FDF Dossiers, 52 FDA Orange Book, 64 Europe, 7 Canada, 18 Australia, 37 South Africa, 34 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 150MG/75ML, INJECTABLE;INJECTION - 200MG/100ML, INJECTABLE;INJECTION - 2MG/ML, INJECTABLE, LIPOSOMAL;INJECTION - 20MG/10ML (2MG/ML), INJECTABLE, LIPOSOMAL;INJECTION - 50MG/25ML (2MG/ML)

RELATED EXCIPIENT COMPANIES

1 Faran Shimi Pharmaceutical, 3 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 Actylis, 2 DFE Pharma, 1 Gangwal Chemicals, 14 Kerry, 2 Microlex e.U, 3 Nippon Fine Chemical, 1 Pluviaendo, 2 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

20 Fillers, Diluents & Binders, 8 Parenteral, 7 Direct Compression, 5 Co-Processed Excipients, 4 Granulation, 2 Taste Masking, 2 Coating Systems & Additives, 2 Surfactant & Foaming Agents, 2 Thickeners and Stabilizers, 1 Solubilizers, 1 Emulsifying Agents, 1 Topical